List of Contents

Anti-D Immunoglobulin Market Size, Share, and Trends 2025 to 2034

The global anti-D immunoglobulin market size is calculated at USD 3.42 billion in 2025 and is forecasted to reach around USD 5.55 billion by 2034, accelerating at a CAGR of 5.53% from 2025 to 2034. The North America market size surpassed USD 1.33 billion in 2024 and is expanding at a CAGR of 5.54% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : June 2025
  • Report Code : 6223
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anti-D Immunoglobulin Market 

5.1. COVID-19 Landscape: Anti-D Immunoglobulin Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anti-D Immunoglobulin Market, By Product Type

8.1. Anti-D Immunoglobulin Market Revenue and Volume, by Product Type

8.1.1. Intramuscular Anti-D Immunoglobulin      

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Intravenous Anti-D Immunoglobulin

8.1.2.1. Market Revenue and Volume Forecast

Chapter 9. Global Anti-D Immunoglobulin Market, By Application

9.1. Anti-D Immunoglobulin Market Revenue and Volume, by Application

9.1.1. Hemolytic Disease of the Newborn (HDN)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Rh Immunoprophylaxis during Pregnancy

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Management of Thrombocytopenic Patients

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Anti-D Immunoglobulin Market, By Route of Administration 

10.1. Anti-D Immunoglobulin Market Revenue and Volume, by Route of Administration

10.1.1. Parenteral Administration

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Intravenous Administration

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Subcutaneous Administration

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Anti-D Immunoglobulin Market, By End-User

11.1. Anti-D Immunoglobulin Market Revenue and Volume, by End-User

11.1.1. Hospitals

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Clinics

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Blood Banks

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Research Laboratories

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Anti-D Immunoglobulin Market, By Dosage Form

12.1. Anti-D Immunoglobulin Market Revenue and Volume, by Dosage Form

12.1.1. Liquid Formulation

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Lyophilized Powder Formulation

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Ready-to-Use Formulation

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Anti-D Immunoglobulin Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Product Type

13.1.2. Market Revenue and Volume Forecast, by Application

13.1.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.4. Market Revenue and Volume Forecast, by End-User

13.1.5. Market Revenue and Volume Forecast, by Dosage Form

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Product Type

13.1.6.2. Market Revenue and Volume Forecast, by Application

13.1.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.4. Market Revenue and Volume Forecast, by End-User

13.1.6.5. Market Revenue and Volume Forecast, by Dosage Form  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Product Type

13.1.7.2. Market Revenue and Volume Forecast, by Application

13.1.7.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.4. Market Revenue and Volume Forecast, by End-User

13.1.7.5. Market Revenue and Volume Forecast, by Dosage Form

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Product Type

13.2.2. Market Revenue and Volume Forecast, by Application

13.2.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.4. Market Revenue and Volume Forecast, by End-User  

13.2.5. Market Revenue and Volume Forecast, by Dosage Form  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Product Type

13.2.6.2. Market Revenue and Volume Forecast, by Application

13.2.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.7. Market Revenue and Volume Forecast, by End-User  

13.2.8. Market Revenue and Volume Forecast, by Dosage Form  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Product Type

13.2.9.2. Market Revenue and Volume Forecast, by Application

13.2.9.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.10. Market Revenue and Volume Forecast, by End-User

13.2.11. Market Revenue and Volume Forecast, by Dosage Form

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Product Type

13.2.12.2. Market Revenue and Volume Forecast, by Application

13.2.12.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.12.4. Market Revenue and Volume Forecast, by End-User

13.2.13. Market Revenue and Volume Forecast, by Dosage Form

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Product Type

13.2.14.2. Market Revenue and Volume Forecast, by Application

13.2.14.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.14.4. Market Revenue and Volume Forecast, by End-User

13.2.15. Market Revenue and Volume Forecast, by Dosage Form

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Product Type

13.3.2. Market Revenue and Volume Forecast, by Application

13.3.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.4. Market Revenue and Volume Forecast, by End-User

13.3.5. Market Revenue and Volume Forecast, by Dosage Form

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Product Type

13.3.6.2. Market Revenue and Volume Forecast, by Application

13.3.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.6.4. Market Revenue and Volume Forecast, by End-User

13.3.7. Market Revenue and Volume Forecast, by Dosage Form

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Product Type

13.3.8.2. Market Revenue and Volume Forecast, by Application

13.3.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.8.4. Market Revenue and Volume Forecast, by End-User

13.3.9. Market Revenue and Volume Forecast, by Dosage Form

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Product Type

13.3.10.2. Market Revenue and Volume Forecast, by Application

13.3.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.4. Market Revenue and Volume Forecast, by End-User

13.3.10.5. Market Revenue and Volume Forecast, by Dosage Form

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Product Type

13.3.11.2. Market Revenue and Volume Forecast, by Application

13.3.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.4. Market Revenue and Volume Forecast, by End-User

13.3.11.5. Market Revenue and Volume Forecast, by Dosage Form

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Product Type

13.4.2. Market Revenue and Volume Forecast, by Application

13.4.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.4. Market Revenue and Volume Forecast, by End-User

13.4.5. Market Revenue and Volume Forecast, by Dosage Form

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Product Type

13.4.6.2. Market Revenue and Volume Forecast, by Application

13.4.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.6.4. Market Revenue and Volume Forecast, by End-User

13.4.7. Market Revenue and Volume Forecast, by Dosage Form

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Product Type

13.4.8.2. Market Revenue and Volume Forecast, by Application

13.4.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.8.4. Market Revenue and Volume Forecast, by End-User

13.4.9. Market Revenue and Volume Forecast, by Dosage Form

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Product Type

13.4.10.2. Market Revenue and Volume Forecast, by Application

13.4.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.4. Market Revenue and Volume Forecast, by End-User

13.4.10.5. Market Revenue and Volume Forecast, by Dosage Form

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Product Type

13.4.11.2. Market Revenue and Volume Forecast, by Application

13.4.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.4. Market Revenue and Volume Forecast, by End-User

13.4.11.5. Market Revenue and Volume Forecast, by Dosage Form

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Product Type

13.5.2. Market Revenue and Volume Forecast, by Application

13.5.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.4. Market Revenue and Volume Forecast, by End-User

13.5.5. Market Revenue and Volume Forecast, by Dosage Form

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Product Type

13.5.6.2. Market Revenue and Volume Forecast, by Application

13.5.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.6.4. Market Revenue and Volume Forecast, by End-User

13.5.7. Market Revenue and Volume Forecast, by Dosage Form

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Product Type

13.5.8.2. Market Revenue and Volume Forecast, by Application

13.5.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.4. Market Revenue and Volume Forecast, by End-User

13.5.8.5. Market Revenue and Volume Forecast, by Dosage Form

Chapter 14. Company Profiles

14.1. Octapharma

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Kedrion Biopharma

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Grifols

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Saol Therapeutics

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Bayer

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Bio Products Laboratory

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Others

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global anti-D immunoglobulin market is expected to increase from USD 3.24 billion in 2024 to USD 5.55 billion by 2034.

The anti-D immunoglobulin marketis expected to grow at a compound annual growth rate (CAGR) of around 5.53% from 2025 to 2034.

The major players in the anti-D immunoglobulin market include Octapharma Kedrion Biopharma, Grifols, Saol Therapeutics, Bayer, Bio Products Laboratory, and Others.

The driving factors of the anti-D immunoglobulin market are the growing hospitals, clinics, and maternity care facilities, particularly in developing economies, enhance access to Anti-D immunoglobulin products and infrastructure to administer the product.

North America region will lead the global anti-D immunoglobulin market during the forecast period 2025 to 2034.

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Plan your call and get expert insights!

Schedule a Meeting Schedule a Meeting

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us